fingolimod (Gilenya) vs Tascenso ODT

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

fingolimod (Gilenya)

Marketed by Novartis and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT00289978 · Phase 3 · completed

This was a large randomized, triple-blind, placebo-controlled Phase 3 trial in 1,272 people with multiple sclerosis, using the annualized relapse rate as its primary measure. Both fingolimod doses roughly halved that rate against placebo: 0.16 relapses per year (95% CI 0.13 to 0.19) on 1.25 mg and 0.18 (95% CI 0.15 to 0.22) on 0.5 mg, against 0.40 (95% CI 0.34 to 0.47) on placebo. The registry posts these rates without a statistical test, but the intervals do not overlap, so the direction of the effect is not in doubt.

Next expected readout: January 2030 · NCT07220252 (registry estimate)

Reported efficacy

Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) (met)

Result source: NCT00289978

Tascenso ODT

Marketed by Cycle Pharmaceuticals Ltd. and partners

Approved in Multiple Sclerosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfingolimod (Gilenya)Tascenso ODT
Annualised relapse rate0.2 vs 0.4−0.2 vs placebo0.5 mg · wk 104 · n 425NCT00289978
5 other results
  • 0.2 vs 0.4 0.5 mg · wk 104 · n 358 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 429 · Phase 3 · primary NCT00289978
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 370 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 0.5 mg · wk 234 · n 358 · Phase 3 · secondary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 234 · n 370 · Phase 3 · secondary NCT00355134
—Not reported
Free of 3-month confirmed disability progression (%)82.3% vs 75.9%+6.4 vs placebo0.5 mg · wk 104 · n 425NCT00289978
3 other results
  • 74.7% vs 71% 0.5 mg · wk 104 · n 358 · Phase 3 · secondary NCT00355134
  • 83.4% vs 75.9% 1.25 mg · wk 104 · n 429 · Phase 3 · secondary NCT00289978
  • 78.3% vs 71% 1.25 mg · wk 104 · n 370 · Phase 3 · secondary NCT00355134
—Not reported
New or enlarging T2 lesions2.5 vs 9.8−7.3 vs placebo0.5 mg · wk 104 · n 370NCT00289978
1 other result
  • 2.5 vs 9.8 1.25 mg · wk 104 · n 337 · Phase 3 · secondary NCT00289978
—Not reported

Annualised relapse rate

fingolimod (Gilenya)
0.2 vs 0.4−0.2 vs placebo0.5 mg · wk 104 · n 425NCT00289978
5 other results
  • 0.2 vs 0.4 0.5 mg · wk 104 · n 358 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 429 · Phase 3 · primary NCT00289978
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 370 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 0.5 mg · wk 234 · n 358 · Phase 3 · secondary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 234 · n 370 · Phase 3 · secondary NCT00355134
Tascenso ODT
—Not reported

Free of 3-month confirmed disability progression (%)

fingolimod (Gilenya)
82.3% vs 75.9%+6.4 vs placebo0.5 mg · wk 104 · n 425NCT00289978
3 other results
  • 74.7% vs 71% 0.5 mg · wk 104 · n 358 · Phase 3 · secondary NCT00355134
  • 83.4% vs 75.9% 1.25 mg · wk 104 · n 429 · Phase 3 · secondary NCT00289978
  • 78.3% vs 71% 1.25 mg · wk 104 · n 370 · Phase 3 · secondary NCT00355134
Tascenso ODT
—Not reported

New or enlarging T2 lesions

fingolimod (Gilenya)
2.5 vs 9.8−7.3 vs placebo0.5 mg · wk 104 · n 370NCT00289978
1 other result
  • 2.5 vs 9.8 1.25 mg · wk 104 · n 337 · Phase 3 · secondary NCT00289978
Tascenso ODT
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Tascenso ODT: no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fingolimod (Gilenya): 4 of 4 rows · Tascenso ODT: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfingolimod (Gilenya)
Dropout rate
13.2%0.5 mga
NCT00289978 · Phase 3 · monotherapy
show 44 more results
22.6%1.25 mg
NCT00289978 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
7.7%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
13.4%1.25 mg
NCT00340834 · Phase 3 · monotherapy
13.2%0.5 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3
—0.5 mg
NCT00662649 · Phase 3
22.6%1.25 mg
NCT00662649 · Phase 3 · monotherapy
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
9.1%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
13.8%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
33.3%
NCT02232061 · Phase 4 · registry result, not featured evidence
43%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
15.7%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
31%
NCT01705236 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
18.2%FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
0.5%
NCT01585298 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
8%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
7.5%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
14.2%
NCT01623596 · Phase 4 · registry result, not featured evidence
12.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
16.7%
NCT01578330 · Phase 4 · registry result, not featured evidence
5.2%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
9.6%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
—0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
15.6%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
6.8%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
24%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
32.2%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
2.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
19.1%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
21.7%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%0.5 mga
NCT00289978 · Phase 3 · monotherapy
show 44 more results
5.1%1.25 mg
NCT00289978 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
2.1%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
6.1%1.25 mg
NCT00340834 · Phase 3 · monotherapy
3.1%0.5 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3
—0.5 mg
NCT00662649 · Phase 3
5.1%1.25 mg
NCT00662649 · Phase 3 · monotherapy
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
0%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
2.3%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
—
NCT02232061 · Phase 4 · registry result, not featured evidence
15.2%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.7%
NCT01705236 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
4.5%FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
0.3%
NCT01585298 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
2%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
0.7%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
4.6%
NCT01623596 · Phase 4 · registry result, not featured evidence
9.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
4.8%
NCT01578330 · Phase 4 · registry result, not featured evidence
3%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
5.1%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
—0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
4.1%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
1.2%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
6.1%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
7.6%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
1.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
12.8%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
4.3%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
Serious AEs
10.1%0.5 mga
NCT00289978 · Phase 3 · monotherapy
show 44 more results
11.9%1.25 mg
NCT00289978 · Phase 3 · monotherapy
7%0.5 mg
NCT00340834 · Phase 3 · monotherapy
14.5%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
10.7%1.25 mg
NCT00340834 · Phase 3 · monotherapy
15.3%1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3 · monotherapy
9.4%0.5 mg
NCT00662649 · Phase 3
7.1%0.5 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
10.7%1.25 mg
NCT00662649 · Phase 3
11.7%1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
33.3%
NCT02232061 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
12.6%
NCT01705236 · Phase 4 · registry result, not featured evidence
4.5%0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
—FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
2.3%
NCT01585298 · Phase 4 · registry result, not featured evidence
0%0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
5.5%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
2.7%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
8.7%0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
6.7%
NCT01623596 · Phase 4 · registry result, not featured evidence
6.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
9.5%
NCT01578330 · Phase 4 · registry result, not featured evidence
0.9%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
4%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
3.6%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
12.6%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
7.4%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
14.8%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
6.5%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
14.3%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
8.8%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
1.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
17%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
10.9%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
0.5 mga
nasopharyngitis 27.1% (placebo 27.5%)
headache 25.2% (placebo 23%)
upper respiratory tract infection 17.2% (placebo 17.2%)
NCT00289978 · Phase 3 · monotherapy
show 34 more results
1.25 mg
headache 26.3% (placebo 23%)
nasopharyngitis 26.1% (placebo 27.5%)
upper respiratory tract infection 14.5% (placebo 17.2%)
NCT00289978 · Phase 3 · monotherapy
0.5 mg
headache 23.1%
nasopharyngitis 20.5%
fatigue 10.3%
NCT00340834 · Phase 3 · monotherapy
0.5 mg
nasopharyngitis 31%
headache 20.5%
lymphopenia 14.7%
NCT00340834 · Phase 3 · monotherapy
1.25 mg
headache 22.9%
nasopharyngitis 22.1%
fatigue 14.3%
NCT00340834 · Phase 3 · monotherapy
1.25 mg
nasopharyngitis 31.3%
lymphopenia 21.4%
headache 17.1%
NCT00340834 · Phase 3 · monotherapy
0.5 mg
nasopharyngitis 25.4%
upper respiratory tract infection 17.5%
lymphopenia 15.7%
NCT00662649 · Phase 3
0.5 mg
nasopharyngitis 28.4%
headache 16.8%
upper respiratory tract infection 15.5%
NCT00662649 · Phase 3
1.25 mg
nasopharyngitis 28.4%
lymphopenia 18%
upper respiratory tract infection 13.5%
NCT00662649 · Phase 3
1.25 mg
nasopharyngitis 26.9%
upper respiratory tract infection 15.9%
headache 12.4%
NCT00662649 · Phase 3
anxiety 16.7%
bursitis 16.7%
facet joint syndrome 16.7%
NCT02232061 · Phase 4 · registry result, not featured evidence
0.5 mg
headache 8%
lymphopenia 5.5%
pain in extremity 5.5%
NCT03257358 · Phase 4 · registry result, not featured evidence
0.5 mg
fall 5.5%
urinary tract infection 3.2%
arthralgia 2.8%
NCT03257358 · Phase 4 · registry result, not featured evidence
nasopharyngitis 47.1%
multiple sclerosis relapse 24.1%
hypertension 13.8%
NCT01705236 · Phase 4 · registry result, not featured evidence
0.5 mg
influenza 3%
gamma-glutamyltransferase increased 1.5%
headache 1.5%
NCT02373098 · Phase 4 · registry result, not featured evidence
headache 4.5%
fatigue 3.2%
nasopharyngitis 2%
NCT01585298 · Phase 4 · registry result, not featured evidence
0.5 mg
blood immunoglobulin m decreased 0.8%
NCT02720107 · Phase 4 · registry result, not featured evidence
headache 8.5%
nasopharyngitis 8%
upper respiratory tract infection 7.5%
NCT01498887 · Phase 4 · registry result, not featured evidence
headache 11.6%
urinary tract infection 10.2%
upper respiratory tract infection 8.2%
NCT01498887 · Phase 4 · registry result, not featured evidence
0.5 mg
headache 10.6%
alanine aminotransferase increased 8.7%
depression 6.7%
NCT01333501 · Phase 4 · registry result, not featured evidence
fatigue 11.3%
nasopharyngitis 9.5%
headache 9.2%
NCT01623596 · Phase 4 · registry result, not featured evidence
exacerbation of migraines 3%
NCT02048072 · Phase 4 · registry result, not featured evidence
urinary infection 21.4%
upper respiratory infection 19%
lymphopenia 16.7%
NCT01578330 · Phase 4 · registry result, not featured evidence
0.5 mg
lymphopenia 11.7%
gamma-glutamyltransferase increased 5.7%
alanine aminotransferase increased 4.8%
NCT01534182 · Phase 4 · registry result, not featured evidence
0.5 mg/day
headache 12.4%
fatigue 11.5%
upper respiratory tract infection 6.5%
NCT01216072 · Phase 4 · registry result, not featured evidence
0.5 mg/day
headache 9.8%
nausea 5.7%
fatigue 5.2%
NCT01216072 · Phase 4 · registry result, not featured evidence
0.5 mg/Day
nasopharyngitis 17.3%
headache 8.5%
upper respiratory tract infection 8.5%
NCT01201356 · Phase 3 · registry result, not featured evidence
0.5 mg
headache 13.6%
lymphopenia 10.5%
fatigue 6.2%
NCT01497262 · Phase 3 · registry result, not featured evidence
0.5 mg
upper respiratory tract infection 24.3% (placebo 24.2%)
nasopharyngitis 23.5% (placebo 23.9%)
headache 23.2% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16% (placebo 23.9%)
upper respiratory tract infection 12.3% (placebo 24.2%)
headache 9% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
1.25 mg
upper respiratory tract infection 24.9% (placebo 24.2%)
nasopharyngitis 23.8% (placebo 23.9%)
headache 21.9% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
1.25 mg
nasopharyngitis 16.2% (placebo 23.9%)
upper respiratory tract infection 15.9% (placebo 24.2%)
sinusitis 10.1% (placebo 12.7%)
NCT00355134 · Phase 3 · registry result, not featured evidence
headache 18.9% (placebo 9.3%)
nasopharyngitis 15.8% (placebo 18.6%)
upper respiratory tract infection 11.6% (placebo 14%)
NCT01199861 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 61.7%
headache 17%
liver function test abnormal 12.8%
NCT00670449 · Phase 2 · registry result, not featured evidence
1.25 mg
nasopharyngitis 60.9%
liver function test abnormal 17.4%
lymphopenia 17.4%
NCT00670449 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fingolimod (Gilenya)

Annualized Relapse 0.18 vs 0.4 placebo per year @ 104wk0.5 mg
event rate · per year
NCT00289978 · Phase 3 · monotherapy
show 5 more results
0.208 vs 0.403 placebo per year @ 104wk0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
0.192 vs 0.363 placebo per year @ 234wk0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
0.16 vs 0.4 placebo per year @ 104wk1.25 mg
NCT00289978 · Phase 3 · monotherapy
0.203 vs 0.403 placebo per year @ 104wk1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
0.18 vs 0.363 placebo per year @ 234wk1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
EDSS 3mo Disability Progression-free 82.3% (n=425) vs 75.9% (n=418) placebo @ 104wk0.5 mg
responder rate · % of participants
NCT00289978 · Phase 3 · monotherapy
show 3 more results
74.7% (n=358) vs 71% (n=355) placebo @ 104wk0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
83.4% (n=429) vs 75.9% (n=418) placebo @ 104wk1.25 mg
NCT00289978 · Phase 3 · monotherapy
78.3% (n=370) vs 71% (n=355) placebo @ 104wk1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
New or Enlarging T2 Lesion 2.5 vs 9.8 placebo lesions @ 104wk0.5 mg
event count · lesions
NCT00289978 · Phase 3 · monotherapy
show 1 more result
2.5 vs 9.8 placebo lesions @ 104wk1.25 mg
NCT00289978 · Phase 3 · monotherapy
Annualized Relapse 0.161 per year @ 52wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 17 more results
0.182 per year @ 104wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.11 per year @ 156wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
NA per year @ 208wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.539 per year @ 26wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.227 per year @ 52wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.166 per year @ 104wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.191 per year @ 156wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.164 per year @ 208wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.203 per year @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.156 per year @ 104wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.116 per year @ 156wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
NA per year @ 208wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.404 per year @ 26wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.284 per year @ 52wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.223 per year @ 104wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.058 per year @ 156wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.075 per year @ 208wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
New T2 Lesion 1.6 T2 lesions @ 52wk0.5 mg
event count · T2 lesions
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 7 more results
0.87 T2 lesions @ 104wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
1.04 T2 lesions @ 156wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.59 T2 lesions @ 208wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
1.6 T2 lesions @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
1.08 T2 lesions @ 104wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
1.4 T2 lesions @ 156wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.97 T2 lesions @ 208wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
EDSS 3mo Disability Progression-free 94.1% (n=429) @ 52wk0.5 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 1 more result
93.3% (n=420) @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
Annualized Relapse 0.166 per year @ 234wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
Month 0 to end of study, n=420, 429, 431
NCT00340834 · Phase 3 · monotherapy
show 1 more result
0.192 per year @ 234wk1.25 mg
Month 0 to end of study, n=420, 429, 431
NCT00340834 · Phase 3 · monotherapy
New T2 Lesion 0.86 T2 lesions @ 234wk0.5 mg
event count · T2 lesions
Extension (open-label)
No placebo or comparator arm
Last MRI scan to end of study, n=275, 309, 290
NCT00340834 · Phase 3 · monotherapy
show 1 more result
1.75 T2 lesions @ 234wk1.25 mg
Last MRI scan to end of study, n=275, 309, 290
NCT00340834 · Phase 3 · monotherapy
EDSS 6mo Disability Progression Free 71.28% (n=429) @ 13wk0.5 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 3 more results
79.76% (n=429) @ 26wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
67.01% (n=420) @ 13wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
79.54% (n=420) @ 26wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
Relapse Rate Annualized 0.185 per year @ 260wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 9 more results
0.111 per year @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.292 per year @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.095 per year @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.13 per year @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.164 per year @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.064 per year @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.301 per year @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.074 per year @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.164 per year @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
Relapse-free 59.29% (n=425) @ 260wk0.5 mg
absolute value · percentage points
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 1 more result
59.85% (n=429) @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
no New or Enlarged T2 Lesion 50.3% (n=163) @ 104wk0.5 mg
absolute value · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 23 more results
23.2% (n=69) @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
69.3% (n=163) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
55.1% (n=69) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
69.4% (n=57) @ 13wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
86% (n=57) @ 26wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
88.6% (n=57) @ 39wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
93.2% (n=57) @ 52wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
88.4% (n=57) @ 78wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
94.9% (n=57) @ 104wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92% (n=57) @ 156wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
100% (n=57) @ 208wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
53.2% (n=126) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
18.5% (n=65) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
57.1% (n=126) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
52.3% (n=65) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
60% (n=54) @ 13wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
91.5% (n=54) @ 26wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92.3% (n=54) @ 39wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
95.2% (n=54) @ 52wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
90% (n=54) @ 78wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92.3% (n=54) @ 104wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
90.5% (n=54) @ 156wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
100% (n=54) @ 208wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence

+ 144 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fingolimod (Gilenya)'s landscape · Tascenso ODT's landscape